Treatment of Glucagonoma-Related Necrolytic Migratory Erythema With Peptide Receptor Radionuclide Therapy.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Dec 2021
01 Dec 2021
Historique:
pubmed:
26
5
2021
medline:
9
11
2021
entrez:
25
5
2021
Statut:
ppublish
Résumé
Glucagonomas are rare types of pancreatic neuroendocrine tumors. They may present with a clinical entity called glucagonoma syndrome, which includes necrolytic migratory erythema as a skin component. Here we present a 26-year-old woman experiencing ongoing skin lesions, excessive weight loss, and nausea. She was diagnosed with metastatic glucagonoma. Her 68Ga-DOTATATE PET/CT showed increased uptake at the primary pancreatic lesion and hepatic metastases. She received 2 cycles of peptide receptor radionuclide therapy and had a partial response with a near-complete regression of her skin lesions.
Identifiants
pubmed: 34034327
doi: 10.1097/RLU.0000000000003731
pii: 00003072-202112000-00013
doi:
Substances chimiques
Radioisotopes
0
Receptors, Peptide
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1002-1003Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Tierney EP, Badger J. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. MedGenMed . 2004;6:4.
Lobo I, Carvalho A, Amaral C, et al. Glucagonoma syndrome and necrolytic migratory erythema. Int J Dermatol . 2010;49:24–29.
Tremblay C, Marcil I. Necrolytic migratory erythema: a forgotten paraneoplastic condition. J Cutan Med Surg . 2017;21:559–561.
Mullans EA, Cohen PR. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema. J Am Acad Dermatol . 1998;38:866–873.
Fuller C, Glick J, Rivas S, et al. Necrolytic migratory erythema associated with fatty liver disease and the psuedoglucagonoma syndrome. Dermatol Online J . 2016;22:13030/qt8108d88h.
Batcher E, Madaj P, Gianoukakis AG. Pancreatic neuroendocrine tumors. Endocr Res . 2011;36:35–43.
John AM, Schwartz RA. Glucagonoma syndrome: a review and update on treatment. J Eur Acad Dermatol Venereol . 2016;30:2016–2022.
Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res . 2004;120:139–161.
Tolliver S, Graham J, Kaffenberger BH. A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema. Int J Dermatol . 2018;57:642–645.
Liu JW, Qian YT, Ma DL. Necrolytic migratory erythema. JAMA Dermatol . 2019;55:1180.
V’lckova-Laskoska M, Balabanova-Stefanova M, Arsovska-Bezhoska I, et al. Necrolytic migratory erythema: complete healing after surgical removal of pancreatic carcinoma. Acta Dermatovenerol Croat . 2018;26:329–332.
Jiménez-Gallo D, Ossorio-García L, de la Varga-Martínez R, et al. Necrolytic migratory erythema associated with glucagonoma treated successfully with cyclosporine. Dermatol Ther . 2017;30.